Louis Katz
Infectious Disease · Davenport, IANPI 1083608772
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,163 of the $11,772 with a category attached, or 60.9%. 7 manufacturers reported payments, led by Ortho-clinical Diagnostics, Inc. at 34.3% of the total. Reporting peaked in 2020 at $6,038 and has fallen 99.1% since, to $52 in 2024. Among infectious disease clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 16 payments — averaging $735.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ortho-clinical Diagnostics, Inc.$4K
- Terumo BCT, Inc.$3K
- Roche Molecular Systems, Inc.$3K
- Biomerieux Inc$1K
- Grifols Diagnostic Solutions, Inc.$67
- Carter Bloodcare$25
- plus $15 from 1 others
Across 72 payments — averaging $10,691 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Molecular Systems, Inc.$767K
- Terumo BCT, Inc.$2K
What the payments were for
- Consulting fees$4,41037%
- Speaking & faculty fees$7,16361%
- Food & beverage$1321%
- Education$671%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ortho-clinical Diagnostics, Inc. | 2 | $4,038 |
| Terumo BCT, Inc. | 7 | $3,476 |
| Roche Molecular Systems, Inc. | 3 | $3,151 |
| Biomerieux Inc | 1 | $1,000 |
| Grifols Diagnostic Solutions, Inc. | 1 | $67 |
| Carter Bloodcare | 1 | $25 |
| Gilead | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,772 in reported general payments places this provider in the 95th percentile of 58 infectious disease providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DescovyEmtricitabine/Tenofov Alafenam | 35 | $73,303 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 19 | $1,178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadDescovy | $15 | $73,30335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 58 infectious disease providers in Iowa.
Other infectious disease in Davenport
- Bharat MotwaniDavenport$1K
- Felipe BarbosaDavenport$116
- Ravi VemuriDes Moines$16K
- Michael OhlIowa City$9K
- Upinder SinghIowa City$8K
- Karen BrustIowa City$4K
- Patricia WinokurIowa City$3K
- Daniel LampteySioux City$2K
- Ami PatelWaterloo$2K
- Aneesa AfrozeDes Moines$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.